交易 Capricor Therapeutics Inc - CAPR
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company advancing cell- and exosome-based therapies for cardiac and neuromuscular disorders. Its lead program, CAP-1002, is in late-stage trials for Duchenne muscular dystrophy (DMD), with potential for FDA breakthrough designation. The company also develops exosome-based platforms for RNA delivery. Capricor offers investors high-upside, development-stage exposure to regenerative medicine and orphan diseases.最新股票文章

SpaceX上市首日收涨19%——IPO后如何交易SpaceX SPCX差价合约
SpaceX(SPCX)于2026年6月12日在纳斯达克首次上市,开盘报150美元,收盘报160.95美元,较135美元的IPO发行价上涨19.2%。
08:41, 16 六月 2026
Reuters News•Europe
20:48 (UTC), 30 undefined 2026Reuters News•Europe
18:56 (UTC), 30 undefined 2026Reuters News•Europe
15:47 (UTC), 30 undefined 2026Reuters News•Europe
15:14 (UTC), 30 undefined 2026Reuters News•Europe
12:03 (UTC), 30 undefined 2026Reuters News•Europe
12:01 (UTC), 30 undefined 2026Reuters News•Europe
21:09 (UTC), 29 undefined 2026Reuters News•Europe
20:52 (UTC), 29 undefined 2026Reuters News•Europe
12:50 (UTC), 27 undefined 2026

